e-learning
resources
ERJ
2001
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Do we need controlled clinical trials in pulmonary arterial hypertension?
Galie N.
Source:
Eur Respir J 2001; 17: 1-3
Journal Issue:
January
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Galie N.. Do we need controlled clinical trials in pulmonary arterial hypertension?. Eur Respir J 2001; 17: 1-3
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Source: Eur Respir J 2009; 34: 231-242
Year: 2009
Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018
Year: 2018
New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension
Source: Eur Respir Rev 2013; 22: 495-502
Year: 2013
Clinical trial design and new therapies for pulmonary arterial hypertension
Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018
Year: 2019
Clinical trials in pulmonary arterial hypertension: what they tell us
Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Year: 2020
Clinical trials in pulmonary arterial hypertension: what do they tell us
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
Clinical trials in pulmonary arterial hypertension: what do they tell us
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial
Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension
Year: 2020
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value
Source: Eur Respir J 2007; 29: 432-434
Year: 2007
Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
The future of treatment for pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
The future of treatment for pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
The future of treatment for pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012
The future of treatment for pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept